Auxilium inked a co-promote deal with GSK on its Testim 1% testosterone gel for the US.

Novo Nordisk expanded its motorsports initiative, while online firm Health Union launched a mobile app designed to help patients monitor migraines.

Hitting the 1,000-download mark in less than a week, Haymarket Medical said its new myCME app has been an iTunes top 10 US medical app ever since.

The FDA panel's tepid embrace of Pfizer's RA drug tofacitinib last week has been matched by an equally anemic payer reaction.

Physician social network adoption was flat from 2011-2012, a survey says, and Everyday Health gets a nom for a daytime Emmy

FDA panel votes for second weight loss drug this year, Gilead's HIV treatment gets panel nod

Reports that Pfizer is pulling out of the Lipitor business are somewhat premature, spokesperson MacKay Jimeson told MM&M.

GlaxoSmithKline is once again in hot pursuit of Human Genome Sciences. The company is back with the same $2.6 billion bid, but this time rather than asking HGSI to join GSK the Britain-based firm is offering $13 a share in cash. Meanwhile, Teva reported first quarter sales hit $5B.

For anyone who thought Pfizer's RA candidate tofacitinib would sail through its review tomorrow with an FDA advisory committee, documents released ahead of the meeting indicate the devil's in the details.

Abbott settled a massive federal and state lawsuit over off-label marketing of Depakote to the tune of $1.5 billion and a token guilty plea - on one violation of the FD&C Act, for misbranding - along with a five-year Corporate Integrity Agreement.

Novartis said Thursday that generics subsidiary Sandoz is purchasing Fougera Pharmaceuticals for $1.5 billion in cash. In other news, Boehringer Ingelheim launched what it called the largest observational study of non-valvular atrial fibrillation patients.

Elsevier took over as publisher of The American Journal of Geriatric Psychiatry. In other news, Eli Lilly opened its new Erl Wood research facility Monday.

Biogen Idec reported $975 million in product sales for the quarter ended March 31, up 7.5% compared to sales for the same period last year. In other news, Targacept and AstraZeneca have officially parted ways over the experimental anti-depressant drug known as TC-5214, according to a report.

The FDA, as expected, told Amgen that it could not OK the biotech's request to expand the approval for Xgeva into pre-metastases bone cancer, Amgen said.

Better than expected US sales of Plavix helped Bristol-Myers Squibb power through the first quarter with a 5% revenue gain over the first quarter of 2011, while Shire announced quarter product sales of $1.1 billion for the quarter, a 24% increase over the year-ago period. A Walgreen Co. study shows that discount prescription programs and pharmacists can have a major impact on keeping patients on their medication regimens.

Despite plummeting Zyprexa sales and a forecast of tough times yet to come, Eli Lilly remained upbeat during Wednesday's first-quarter earnings call. Meanwhile, GlaxoSmithKline's CEO Andrew Witty said Wednesday that the $10.5 billion in sales his firm earned for the first quarter of 2012, a 2% bump over the same period last year, is a sign that the company's progress is on track.

GlaxoSmithKline continues to shed businesses, but can't shake its weight-loss drug Alli (orlistat).

Abbott Laboratories announced Monday it was expanding its relationship with St. Jude Medical. The new agreement expands on a 2008 partnership.

A genetic study of breast cancer has found ten distinct types of the disease and ferreted out "a slew" of previously unknown genetic factors that influence the cancer's aggressiveness.

Abbott Laboratories announced Wednesday that sales hit $9.5 billion for the quarter ended March 31, a 4.6% increase over the same period last year. Meanwhile, Pfizer's move to separate itself from its nutrition business is rumored to be gaining momentum and the pharmaceutical industry landed two spots on CR Magazine's list of top corporate citizens, with BMS earning top marks.